Skip to main content
. Author manuscript; available in PMC: 2021 Dec 6.
Published in final edited form as: Br J Haematol. 2019 Apr 10;186(2):286–299. doi: 10.1111/bjh.15902

Fig 6.

Fig 6.

Makers of inflammation and contamination in SCD BM are elevated regardless of anticoagulant or day of processing. (A) Comparison of SCD BM drawn in heparin versus ACDA using combined data from day 0 + day 1 (n = 19 in each condition). (B) Comparison of SCD marrow processed immediately or on day one using combined data from heparin + ACDA (n = 19 in each condition). (C) Flow cytometry results for each anticoagulant and processing day (n = 19 in each condition). A P-value of <0·01 was considered statistically significant. ACDA, acid citrate dextrose-A; BM, bone marrow; SCD, sickle cell disease.